Antihypertensive and lipid-lowering treatment to prevent heart attack trial
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) trial compared major outcomes in high risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic.
Design
Randomized, double-blind, multi-center clinical trial
Endpoint
Determine whether occurrence of fatal CHD or nonfatal MI is lower for high-risk hypertensive patients treated with newer agents (CCB, ACEI, alpha-blocker) compared with a diuretic
Population
42,418 high-risk hypertensive patients ≥ 55 years
Results
The alpha blocker arm (doxazosin) was dropped early due to futility.